2016-09-12 15:34:22 UTC
Sept. 12, 2016
Dr. Colin Howden discusses the highs and lows of drug development for gastroesophageal reflux disease in a new blog post.
In the early 1990s, there was much optimism concerning the treatment of gastroesophageal reflux disease (GERD). Now, things are less clear. Gastroenterologists across the U.S. frequently see patients diagnosed, or misdiagnosed, with GERD who are dissatisfied with PPI treatment.
How did this go wrong? Have we set patients’ expectations of PPI treatment too high? In clinical trials, have we focused on the wrong end points?
In a new blog post on Applied Clinical Trials, Colin Howden, MD, AGAF, chair of the AGA Center for Diagnostics and Therapeutics, provides his take on drug development for GERD over the last 20-plus years. In addition to discussing the successes and challenges, he also outlines the path forward to improving the options for patients suffering from GERD.
Read the blog post on Applied Clinical Trials.
Dr. Howden’s post is part of a new series in Applied Clinical Trials on drug development in GI, sponsored by the AGA Center for Diagnostics and Therapeutics. The first post in the series, by Evan S. Dellon, MD, MPH, focused on clinical trials in eosinophilic esophagitis, and the second, authored by William Hasler, MD, discussed treatment for gastroparesis.
Interested in the topic of drug development for upper GI disorders? The AGA Center for Diagnostics and Therapeutics will be holding its first Drug Development Conference, Oct. 27 and 28, 2016, in Washington, DC, to discuss the challenges facing drug development in upper GI disorders, and to help navigate a path forward. If you are involved in drug development for GERD, gastroparesis, EOE or functional dyspepsia, join the center for this interactive meeting. Learn more and reserve your spot today.